Table 1. Clinical characteristics of the 23 childhood AML patients in this study at presentation and first relapse.

Pair	Sex	FAB type	Cytogenetics	Blast% diagnosis	Blast% relapse	Time to relapse	Follow-up time	Dead
1	M	M5	MLL t(10;11)	90	86	9.7	10.1	Yes
2	M	M2	Normal	93	82	3.7	9.2	Yes
3	M	M2	Loss Y	86	90	10.4	18	Yes
4	M	M4	t(6;9)	89	88	8.5	14.8	Yes
5	M	M5	Complex	88	84	8.9	9.2	Yes
6	M	M1	Unknown	91	86	14.8	19	Yes
7	M	M5	t(6;9)	93	89	5.7	12.3	Yes
8	M	M5	t(6;21)	96	82	15.8	26.3	Yes
9	F	M5	MLL t(9;11)	99	90	6.2	NA	No
10	M	M1	Unknown	82	93	11.4	14.9	Yes
11	M	M2	AML-ETO	91	94	58.4 1	164.7	No
12	M	M2	AML-ETO	91	91	12.6	101.2	No
13	M	M2	AML-ETO	88	83	8.9	15.5	Yes
14	M	M0	Complex	93	91	2.6	20.8	No
15	M	M2	AML-ETO	95	97	7.7	18.5	Yes
16	F	M4	t(11;20)	90	89	9.8	19	Yes
17	M	M4	MLL t(10;11)	93	83	5.9	9.1	No
18	F	M2	Normal	84	81	15.3	16.3	Yes
19	M	M2	AML-ETO	95	93	14.1	53.7	No
20	M	M4	Del 9	89	96	8.7	20.6	No
21	M	M4	Normal	86	88	6.9	9.9	Yes
22	F	M4	MLL t(9;11)	90	95	8.7	21.5	Yes
23	M	M5	Del 7	93	92	14.4	215.7	Yes

Time to relapse and follow-up time are given in months

¹patient 11 has follow-up time of > 2 years; Blast% after enrichment.